In addition, in the baseline subgroup receiving monoamine oxidase B inhibitors (MAO-B), Prasinezumab showed a more significant effect in inhibiting symptom deterioration, whose outstanding performance may be related to the speed and degree of aggregation of alpha synuclein, suggesting that intervention with aggregated alpha synuclein may be more effective in rapidly progressing PD subtypes [205]. This evidence concerns the gene MAOB and Parkinson disease.